Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AIR645
- Development stage
- Phase 2
- Lead developer
- Intelligent Surgical Instruments and Systems
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Inhalation
01
Overview
AIR645 is a second-generation, modified antisense oligonucleotide drug developed for inhalation. It targets the alpha subunit of the human interleukin-4 receptor (IL-4Rα), which is also required for interleukin 13 (IL-13) activity, thereby inhibiting both IL-4 and IL-13 signaling pathways. These cytokines are key mediators in allergic inflammation and asthma pathogenesis. The drug was designed to suppress asthmatic responses by blocking dual cytokine signaling involved in airway inflammation. Developed originally by Isis Pharmaceuticals (now Ionis) and later by Altair Therapeutics, AIR645 reached phase 2 clinical trials for asthma and allergic asthma but was discontinued after these studies[2][3][5].
- Other names
- AIR 645AIR645AIR-645ISIS-369645ISIS369645ISIS 369645
02
Targets
IL4R (Interleukin-4 receptor alpha subunit)
Beyond the preview
Go deeper on AIR645.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AIR645.